- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03356262
The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort (QUALITY)
Study Overview
Status
Detailed Description
The QUALITY Cohort is funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, as well as the Fonds de la recherche en santé du Québec. The multidisciplinary study team comprises over 20 researchers with a wide variety of relevant expertise as well as research fellows, students and staff (www.etudequalitystudy.ca).
The specific objectives of QUALITY are: 1) To increase understanding of the natural history of excess weight and its associated cardiometabolic consequences (dyslipidemia, hyperinsulinemia, dysglycemia, inflammation, elevated blood pressure, sympathetic overactivity) in youth at risk for the development of obesity; 2) To investigate the relative importance of the genetic, biological, environmental and psychosocial determinants of excess weight and its associated cardiometabolic consequences. Determinants of particular interest include social factors (socio-economic status, family composition, built environment), behavioural factors (eating behaviour, physical activity, smoking, sleep, stress), biological factors (adverse fetal environment, body fat distribution, growth trajectory, aerobic fitness), metabolic factors (insulin sensitivity, adipocytokines), and genetic/familial factors (family history, parental characteristics, gene variations); 3) To examine the relation between obesity, cardiometabolic complications, and subclinical markers of atherosclerosis; and 4) To examine whether obesity and its associated risk factor are related to children's oral health.
The QUALITY Cohort used a school-based sampling strategy to identify potential participants. About 400 000 recruitment flyers were distributed over three consecutive years to parents of children in Grades 2 to 5, in 1040 primary schools (89% of schools approached) including 44 private schools situated within 75 km of Montreal, Quebec City and Sherbrooke in the province of Quebec, Canada. Families interested in participating were invited to contact the research coordinator for additional information, to confirm eligibility, and to set an appointment with the research team; 1320 of 3350 families who contacted the coordinator met the inclusion criteria. Six hundred and thirty families agreed to participate and completed the baseline evaluation.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
630 Caucasian families with a child aged 8-10 years agreed to participate and completed the baseline evaluation.
564 families completed the second round of data collection 2 years later. 377 families completed the third round of data collection 7 years after the baseline assessment.
A 4th round of data collection is currently being prepared.
Description
Inclusion Criteria:
- Children aged 8-10 years at baseline;
- Caucasian of Western European ancestry;
- At least one obese biological parent (i.e., body mass index (BMI) ≥30 kg/m2 or waist circumference >102 cm in men and >88 cm in women, based on self-reported measurements of height, weight and waist circumference)
- Both biological parents available to participate in the baseline assessment.
Exclusion Criteria:
- Children with a previous diagnosis of Type 1 or 2 diabetes;
- Children with a previous diagnosis of a serious illness, psychological condition, or cognitive disorder which hindered participation in some or all of the study components;
- Children treated with anti-hypertensive medication or steroids (except if administered topically or through inhalation);
- Children following a very restricted diet (< 600 kcal/day);
- Mother pregnant or breastfeeding at the baseline evaluation;
- Family with pending plans to move out of the province of Quebec (Canada).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body mass index (BMI)
Time Frame: Through study completion, 13 - 14 years post baseline
|
Weight (kg) and height (m) will be combined to report BMI in kg/m^2 and transformed to z-scores using WHO standards
|
Through study completion, 13 - 14 years post baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Waist circumference
Time Frame: Through study completion, 13 - 14 years post baseline
|
Measured in centimeters, midway between the last floating rib and the iliac crest
|
Through study completion, 13 - 14 years post baseline
|
|
% body fat mass
Time Frame: Through study completion, 13 - 14 years post baseline
|
Measured using dual energy x-ray absorptiometry and combined as total body fat mass in kg / total body mass in kg * 100
|
Through study completion, 13 - 14 years post baseline
|
|
Impaired fasting glucose
Time Frame: Through study completion, 13 - 14 years post baseline
|
Measured from a blood sample collected using venipuncture following a 12-hour overnight fast.
Plasma glucose concentrations were computed on the Beckman Coulter Synchron LX20 automat using the glucose oxidase method.
Analyses were performed in batches at the Centre Hospitalier Universitaire Sainte-Justine Clinical Biochemistry laboratory twice monthly.
Considered as impaired fasting blood glucose if greater or equal to 5.6 mmol/L.
|
Through study completion, 13 - 14 years post baseline
|
|
Impaired glucose tolerance
Time Frame: Through study completion, 13 - 14 years post baseline
|
Participants underwent a 2-hour oral glucose tolerance test (OGTT) after a 12-hour overnight fast.
Blood samples were collected at 30-, 60-, 90-, and 120-minute intervals after an oral glucose dose of 1.75 g/kg of body weight (maximum 75 g).
Plasma glucose concentrations were computed on the Beckman Coulter Synchron LX20 automat using the glucose oxidase method.
Analyses were performed in batches at the Centre Hospitalier Universitaire Sainte-Justine Clinical Biochemistry laboratory twice monthly.
Considered as impaired glucose tolerence blood glucose at 2hrs of the OGTT greater or equal to 7.8 mmol/L.
|
Through study completion, 13 - 14 years post baseline
|
|
Type 2 diabetes
Time Frame: Through study completion, 13 - 14 years post baseline
|
Type 2 diabetes was diagnosed according to recognized criteria from the Canadian Diabetes Association (Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Can J Diabetes 2013;37(suppl 1):S1-S212.)
|
Through study completion, 13 - 14 years post baseline
|
|
Hypertension (systolic)
Time Frame: Through study completion, 13 - 14 years post baseline
|
Systolic and diastolic blood pressures (SBP and DBP, respectively) were measured using an appropriately sized arm cuff and an automated oscillometric blood pressure monitor doing 5 repeat measures at 1 min intervals (Dinamap model CR9340).
Participants were seated and had to rest for 5 minutes prior to the measurement.
The average of the last three measures of SBP and DBP was used in the analyses.
These were then transformed to age-, sex-, and height-specific Z-scores according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.
Considered hypertensive if SBP > 95th percentile for age, sex, and height.
|
Through study completion, 13 - 14 years post baseline
|
|
Hypertension (diastolic)
Time Frame: Through study completion, 13 - 14 years post baseline
|
Systolic and diastolic blood pressures (SBP and DBP, respectively) were measured using an appropriately sized arm cuff and an automated oscillometric blood pressure monitor doing 5 repeat measures at 1 min intervals (Dinamap model CR9340).
Participants were seated and had to rest for 5 minutes prior to the measurement.
The average of the last three measures of SBP and DBP was used in the analyses.
These were then transformed to age-, sex-, and height-specific Z-scores according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.
Considered hypertensive if DBP > 95th percentile for age, sex, and height.
|
Through study completion, 13 - 14 years post baseline
|
|
Dyslipidemia
Time Frame: Through study completion, 13 - 14 years post baseline
|
Blood samples were obtained by venipuncture after a 12 hour overnight fast.
Lipids (high density lipoprotein (HDL) cholesterol and triglycerides) were measured on a Synchron LX®20 analyzer, with Beckman Instruments reagents, by the Department of Clinical Biochemistry at CHU Sainte-Justine, according to the recommendations of the International Federation of Clinical Chemistry.
Low density lipoprotein (LDL) cholesterol was calculated based on the Friedewald equation.
Dyslipedimia was defided according to published guidelines (Pediatrics.
2011 Dec; 128(Suppl 5): S213-S256.)
|
Through study completion, 13 - 14 years post baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melanie Henderson, MD, PhD, Université de Montréal
Publications and helpful links
General Publications
- Lambert M, Van Hulst A, O'Loughlin J, Tremblay A, Barnett TA, Charron H, Drapeau V, Dubois J, Gray-Donald K, Henderson M, Lagace G, Low NC, Mark S, Mathieu ME, Maximova K, McGrath JJ, Nicolau B, Pelletier C, Poirier P, Sabiston C, Paradis G. Cohort profile: the Quebec adipose and lifestyle investigation in youth cohort. Int J Epidemiol. 2012 Dec;41(6):1533-44. doi: 10.1093/ije/dyr111. Epub 2011 Jul 23. No abstract available.
- Roberge JB, Harnois-Leblanc S, McNealis V, van Hulst A, Barnett TA, Kakinami L, Paradis G, Henderson M. Body Mass Index Z Score vs Weight-for-Length Z Score in Infancy and Cardiometabolic Outcomes at Age 8-10 Years. J Pediatr. 2021 Nov;238:208-214.e2. doi: 10.1016/j.jpeds.2021.07.046. Epub 2021 Jul 21.
- Van Hulst A, Paradis G, Harnois-Leblanc S, Benedetti A, Drapeau V, Henderson M. Lowering Saturated Fat and Increasing Vegetable and Fruit Intake May Increase Insulin Sensitivity 2 Years Later in Children with a Family History of Obesity. J Nutr. 2018 Nov 1;148(11):1838-1844. doi: 10.1093/jn/nxy189.
- Roberge JB, Van Hulst A, Barnett TA, Drapeau V, Benedetti A, Tremblay A, Henderson M. Lifestyle Habits, Dietary Factors, and the Metabolically Unhealthy Obese Phenotype in Youth. J Pediatr. 2019 Jan;204:46-52.e1. doi: 10.1016/j.jpeds.2018.08.063. Epub 2018 Oct 23.
- Van Hulst A, Paradis G, Benedetti A, Barnett TA, Henderson M. Pathways Linking Birth Weight and Insulin Sensitivity in Early Adolescence: A Double Mediation Analysis. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4524-4532. doi: 10.1210/jc.2018-00525.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QUALITY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark